Heidelberg
Universitätsklinikum Heidelberg
Automated drug screening in ependymoma organoids identifies HDAC, anthracyclines, and proteasome inhibitors as potential therapeutic candidates
Quantification of diverse immune cell subsets in primary meningiomas
Combinatorial drug screening identifies carfilzomib and enzalutamide for the treatment of aggressive meningiomas
The pharmacological atlas of meningiomas
Targeting tumor-associated macrophages in the immune-microenvironment of meningiomas
Prospective longitudinal assessment of health-related quality of life and psycho-oncological burden in meningioma patients after tumor resection
Use of biopsy-derived tumor organoids for personalized drug testing in recurrent glioblastoma